Explore the words cloud of the SLACC project. It provides you a very rough idea of what is the project "SLACC" about.
The following table provides information about the project.
|Coordinator Country||Greece [EL]|
|Total cost||149˙588 €|
|EC max contribution||149˙588 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2015-11-01 to 2016-10-31|
Take a look of project's partnership.
|1||PANEPISTIMIO PATRON||EL (RIO PATRAS)||coordinator||149˙588.00|
This project aims to protect, and commercialize a new panel of transplantable mouse lung cancer cell lines with defined mutation status (MLC) for cancer research and drug discovery. In addition, we aim at disseminating and exploiting a novel method for generating an unlimited pool of such lines from various strains of mice. Human lung cancer is characterized by a variety of mutations in oncogenes (i.e., KRAS) and tumor suppresors (i.e., TRP53), which largely determine whether lung tumors respond to a given therapeutic regime. Human lung cancer cell lines are invaluable for in vitro studies, but need to be propagated in immunodeficient mice, compromising the validity of the results obtained. A panel of syngeneic MLC with a defined and a genetically malleable battery of mutated oncogenes would allow more physiologically relevant studies, would help accelerate research and drug discovery in the field, and would generate substantial interest in the academia and the industry. For the purposes of mother project FP7-IDEAS-ERC-StG-2010-KRASHIMPE-260524 aimed at studying KRAS-driven host-tumor interactions, we derived such MLC lines from the lungs of mice using exposure to tobacco carcinogens or genetic oncogenesis. We request funding to i) characterize MLC lines to show proof-of-concept data that they can be used for drug and oncogene discovery; ii) assemble them into a marketable product; iii) protect these discoveries; iv) assess their market potential; v) attract potential interested parties; and vi) commercialize this new product. We hope the results of this project will speed up investigation and drug discovery by shortening the presently wide time interval between cancer wet bench research and clinical applications.
|year||authors and title||journal||last update|
Konstantina Papadia, Anastasios D. Giannou, Eleni Markoutsa, Christian Bigot, Greejte Vanhoute, Spyridon Mourtas, Annemie Van der Linded, Georgios T. Stathopoulos, Sophia G. Antimisiaris
Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice
published pages: 180-187, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2017.03.010
|European Journal of Pharmaceutical Sciences 102||2019-07-25|
Ioanna Giopanou, Ioannis Lilis, Vassilios Papaleonidopoulos, Theodora Agalioti, Nikolaos I. Kanellakis, Nikolitsa Spiropoulou, Magda Spella, Georgios T. Stathopoulos
Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis
published pages: 00-00, ISSN: 2162-402X, DOI: 10.1080/2162402X.2016.1256528
Konstantina Papadia, Eleni Markoutsa, Spyridon Mourtas, Anastassios D. Giannou, Barabara La Ferla, Fransesco Nicotra, Mario Salmona, Pavlos Klepetsanis, Georgios T. Stathopoulos, Sophia G. Antimisiaris
Multifunctional LUV liposomes decorated for BBB and amyloid targeting. A. In vitro proof-of-concept
published pages: 140-148, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2017.02.019
|European Journal of Pharmaceutical Sciences 101||2019-07-25|
Ioanna Giopanou, Kristina A.M. Arendt, Georgios T. Stathopoulos
Lung carcinogenesis and fibrosis taken together
published pages: 1, ISSN: 1070-5287, DOI: 10.1097/MCP.0000000000000390
|Current Opinion in Pulmonary Medicine||2019-07-25|
Anastasios D Giannou, Antonia Marazioti, Nikolaos I Kanellakis, Ioanna Giopanou, Ioannis Lilis, Dimitra E Zazara, Giannoula Ntaliarda, Danai Kati, Vasileios Armenis, Georgia A Giotopoulou, Anthi C Krontira, Marina Lianou, Theodora Agalioti, Malamati Vreka, Maria Papageorgopoulou, Sotirios Fouzas, Dimitrios Kardamakis, Ioannis Psallidas, Magda Spella, Georgios T Stathopoulos
NRAS destines tumor cells to the lungs
published pages: e201606978, ISSN: 1757-4676, DOI: 10.15252/emmm.201606978
|EMBO Molecular Medicine||2019-07-25|
Y. C. Gary Lee, Steven Idell, Georgios T. Stathopoulos
Translational Research in Pleural Infection and Beyond
published pages: 1361-1370, ISSN: 0012-3692, DOI: 10.1016/j.chest.2016.07.030
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SLACC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SLACC" are provided by the European Opendata Portal: CORDIS opendata.